National Institutes of Health

Description

This program will support the commercial development and validation of novel in vitro human cell-based tools for predicting the responses of individual patients to cystic fibrosis transmembrane conductance regulator (CFTR)-directed therapeutics for cystic fibrosis (CF) lung disease. NHLBI anticipates that outcomes of successful SBIR projects will help attract strategic partners or investors to support ultimate commercialization of a personalized medicine platform that could accelerate translation of CFTR-directed therapy in patients with CF lung disease.

Who can apply

• Small businesses

Contact

NIH OER Webmaster<br/>FBOWebmaster@OD.NIH.GOV<br/>
FBOWebmaster@OD.NIH.GOV